{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T16:39:50Z","timestamp":1781195990214,"version":"3.54.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T00:00:00Z","timestamp":1658361600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T00:00:00Z","timestamp":1658361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s00467-022-05672-5","type":"journal-article","created":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T22:02:23Z","timestamp":1658440943000},"page":"921-925","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Aggressive immunotherapy combined with bortezomib and rituximab for membranous nephropathy associated with enzyme replacement therapy in Pompe disease"],"prefix":"10.1007","volume":"38","author":[{"given":"Keigo","family":"Sasaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Uchimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Inaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masako","family":"Otani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Hanakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5242-8987","authenticated-orcid":false,"given":"Shuichi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,21]]},"reference":[{"key":"5672_CR1","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/01.gim.0000218152.87434.f3","volume":"8","author":"PS Kishnani","year":"2006","unstructured":"Kishnani PS, Steiner RD, Bali D, Berger K et al (2006) Pompe disease diagnosis and management guideline. Genet Med 8:267\u2013288. https:\/\/doi.org\/10.1097\/01.gim.0000218152.87434.f3","journal-title":"Genet Med"},{"key":"5672_CR2","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","volume":"68","author":"PS Kishnani","year":"2007","unstructured":"Kishnani PS, Corzo D, Nicolino M, Byrne B et al (2007) Recombinant human acid \u03b1-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 68:99\u2013109. https:\/\/doi.org\/10.1212\/01.wnl.0000251268.41188.04","journal-title":"Neurology"},{"key":"5672_CR3","doi-asserted-by":"publisher","first-page":"e1116","DOI":"10.1542\/peds.2008-3667","volume":"124","author":"YH Chien","year":"2009","unstructured":"Chien YH, Lee NC, Thurberg BL, Chiang SC et al (2009) Pompe disease in infants: improving the prognosis by newborn screening and early treatment. Pediatrics 124:e1116\u2013e1125. https:\/\/doi.org\/10.1542\/peds.2008-3667","journal-title":"Pediatrics"},{"key":"5672_CR4","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s00415-012-6636-x","volume":"260","author":"A Toscano","year":"2013","unstructured":"Toscano A, Schoser B (2013) Enzyme replacement therapy in late-onset Pompe disease: a systematic literature review. J Neurol 260:951\u2013959. https:\/\/doi.org\/10.1007\/s00415-012-6636-x","journal-title":"J Neurol"},{"key":"5672_CR5","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1681\/ASN.2013030290","volume":"25","author":"D Hanna","year":"2014","unstructured":"Hanna D, Vassili V, Olivia B, Laure-Helene N et al (2014) Allo-immune membranous nephropathy and recombinant aryl sulfatase replacement therapy: a need for tolerance induction therapy. J Am Soc Nephrol 25:675\u2013680. https:\/\/doi.org\/10.1681\/ASN.2013030290","journal-title":"J Am Soc Nephrol"},{"key":"5672_CR6","doi-asserted-by":"publisher","first-page":"e532","DOI":"10.1542\/peds.2003-0988-L","volume":"114","author":"TE Hunley","year":"2004","unstructured":"Hunley TE, Corzo D, Dudek M, Kishnani PS et al (2004) Nephrotic syndrome complicating alpha-glucosidase replacement therapy for Pompe disease. Pediatrics 114:e532\u2013e535. https:\/\/doi.org\/10.1542\/peds.2003-0988-L","journal-title":"Pediatrics"},{"key":"5672_CR7","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1097\/GIM.0b013e3182174703","volume":"13","author":"SG Banugaria","year":"2011","unstructured":"Banugaria SG, Prater SN, Ng YK, Kobori JA et al (2011) The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease. Genet Med 13:729\u2013736. https:\/\/doi.org\/10.1097\/GIM.0b013e3182174703","journal-title":"Genet Med"},{"key":"5672_CR8","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.ymgme.2012.01.019","volume":"105","author":"SG Banugaria","year":"2012","unstructured":"Banugaria SG, Patel TT, Mackey J, Das S et al (2012) Persistence of high sustained antibodies to enzyme replacement therapy despite extensive immuno-modulatory therapy in an infant with Pompe disease: need for agents to target antibody-secreting plasma cells. Mol Genet Metab 105:677\u2013680. https:\/\/doi.org\/10.1016\/j.ymgme.2012.01.019","journal-title":"Mol Genet Metab"},{"key":"5672_CR9","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ymgme.2009.08.003","volume":"99","author":"PS Kishnani","year":"2010","unstructured":"Kishnani PS, Goldenberg PC, DeArmey SL, Heller J et al (2010) Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab 99:26\u201333. https:\/\/doi.org\/10.1016\/j.ymgme.2009.08.003","journal-title":"Mol Genet Metab"},{"key":"5672_CR10","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s00508-013-0475-3","volume":"126","author":"J Markic","year":"2014","unstructured":"Markic J, Polic B, Stricevic L, Metlicic V et al (2014) Effects of immune modulation therapy in the first Croatian infant diagnosed with Pompe disease: a 3-year follow-up study. Wien Klin Wochenschr 126:133\u2013137. https:\/\/doi.org\/10.1007\/s00508-013-0475-3","journal-title":"Wien Klin Wochenschr"},{"key":"5672_CR11","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s10545-010-9209-0","volume":"33","author":"M Rohrbach","year":"2010","unstructured":"Rohrbach M, Klein A, Kohli-Wiesner A, Veraguth D et al (2010) CRIM-negative infantile Pompe disease: 42-month treatment outcome. J Inherit Metab Dis 33:751\u2013757. https:\/\/doi.org\/10.1007\/s10545-010-9209-0","journal-title":"J Inherit Metab Dis"},{"key":"5672_CR12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13023-022-02175-2","volume":"17","author":"HA van Kooten","year":"2022","unstructured":"van Kooten HA, Ditters IAM, Hoogeveen-Westerveld M, Jacobs EH (2022) Antibodies against recombinant human alpha-glucosidase do not seem to affect clinical outcome in childhood onset Pompe disease. Orpanet J Rare Dis 17:31. https:\/\/doi.org\/10.1186\/s13023-022-02175-2","journal-title":"Orpanet J Rare Dis"},{"key":"5672_CR13","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1056\/NEJMc0806809","volume":"360","author":"NJ Mendelsohn","year":"2009","unstructured":"Mendelsohn NJ, Messinger YH, Rosenberg AS, Kishnani PS (2009) Elimination of antibodies to recombinant enzyme in Pompe\u2019s disease. N Engl J Med 360:194\u2013195. https:\/\/doi.org\/10.1056\/NEJMc0806809","journal-title":"N Engl J Med"},{"key":"5672_CR14","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1097\/TP.0b013e318190af83","volume":"86","author":"MJ Everly","year":"2008","unstructured":"Everly MJ, Everly JJ, Susskind B, Brailey P et al (2008) Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation 86:1754\u20131761. https:\/\/doi.org\/10.1097\/TP.0b013e318190af83","journal-title":"Transplantation"},{"key":"5672_CR15","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ymgmr.2015.05.004","volume":"4","author":"EO Stenger","year":"2015","unstructured":"Stenger EO, Kazi Z, Lisi E, Gambello MJ, Kishnani PS (2015) Immune tolerance strategies in siblings with infantile Pompe disease-advantages for a preemptive approach to high-sustained antibody titers. Mol Genet Metab Rep 4:30\u201334. https:\/\/doi.org\/10.1016\/j.ymgmr.2015.05.004","journal-title":"Mol Genet Metab Rep"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-022-05672-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-022-05672-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-022-05672-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T09:06:49Z","timestamp":1673860009000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-022-05672-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,21]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["5672"],"URL":"https:\/\/doi.org\/10.1007\/s00467-022-05672-5","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,21]]},"assertion":[{"value":"15 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}